

NCIC CLINICAL TRIALS GROUP - GI DISEASE SITE COMMITTEE

ESOPHAGEAL / GASTRIC DISEASE ORIENTED WORKING GROUP

AGENDA

OPEN SESSION

Venue: Stevenson Room, Delta Chelsea Hotel

Date: Saturday, May 3rd, 2008

Time: 10:15 am

Chairs: Dr. Rebecca Wong & Dr. Christian Kollmannsberger

-
- | | | |
|----------|--|--------------------------------------|
| 10:15 am | WELCOME AND INTRODUCTION / MEMBERSHIP UPDATE | Dr. R. Wong / Dr. C. Kollmannsberger |
| 10:20am | BRIEF UPDATE OF ACTIVE TRIALS | Dr. R. Wong |
| | ES.2 (TROG 03.01): A Randomized Phase III Study In Advance Oesophageal Cancer To Compare Quality of Life And Palliation Of Dysphasia In Patient Treated With Radiotherapy Versus Chemo-Radiotherapy | |
| | GAC.1 (CALGB-80101): A Phase III Trial Of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma | |
| 10:30 am | INTERGROUP UPDATE | Dr. R. Wong |
| 10:40 am | NEW TRIAL PROPOSALS / CONCEPTS FOR DEVELOPMENT | |
| | DCCG: CRITICS: ChemoRadiotherapy after Induction chemoTherapy In Cancer of the Stomach | Dr. J. Ringash |
| | TROG / AGITG: A randomised phase III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer | Dr. C. Karapetis |
| | NCIC CTG: A multicentre, open-label phase II study of irinotecan, xeloda, and oxaliplatin (IXO) as first line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma | Dr. H-J. Au |
| | NCIC CTG: A phase II/III study of postoperative radiation with oxaliplatin and capecitabine, with or without cetuximab, in operable gastric and gastro-esophageal junction cancer | Dr. T. Niaz / Dr. C. Ferrario |
| | NCIC CTG: Localized esophageal cancer in the elderly patient | Dr. R. Wong |
| 12:00 pm | CLOSING REMARKS & ADJOURNMENT | Dr. R. Wong/Dr. C. Kollmannsberger |